Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium

Toxicology and Applied Pharmacology

Volumn 269, Issue 2, 2013, Pages 121-131

  Gajalakshmi, Palanivel ^a   Priya, Mani Krishna ^a   Pradeep, Thangaraj ^a   Behera, Jyotirmaya ^a   Muthumani, Kandasamy ^a   Madhuwanti, Srinivasan ^a   Saran, Uttara ^a   Chatterjee, Suvro ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

Capecitabine; CGMP; Endothelium; Epirubicin; Nitric oxide; Tamoxifen citrate

Indexed keywords

CAPECITABINE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIRUBICIN; MESSENGER RNA; NITRIC OXIDE; TAMOXIFEN CITRATE;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CATALYSIS; CELL MIGRATION; CELL VIABILITY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; ERYTHROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DOCKING; NONHUMAN; NORMAL HUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELLS, CULTURED; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EPIRUBICIN; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84876726679     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.03.011     Document Type: Article

References (54)

1. Accelrys Software Inc. Discovery Studio Modeling Environment 2011, Accelrys Software Inc. Release 3.1, San Diego.
2. Appel J.M., Jensen B.V., Nielsen D.L., Ryberg M., Zerahn B. Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer. Int. J. Cardiovasc. Imaging 2010, 26:217-223.
3. Atakisi E., Kart A., Atakisi O., Topcu B. Acute tamoxifen treatment increases nitric oxide level but not total antioxidant capacity and adenosine deaminase activity in the plasma of rabbits. Eur. Rev. Med. Pharmacol. Sci. 2009, 13:239-243.
4. Bathina J.D., Yusuf S.W. 5-Fluorouracil-induced coronary vasospasm. J. Cardiovasc. Med. (Hagerstown) 2010, 11:281-284.
5. Cardinale D., Colombo A., Colombo N. Acute coronary syndrome induced by oral capecitabine. Can. J. Cardiol. 2006, 22:251-253.
6. Chang T.K., Weber G.F., Crespi C.L., Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993, 53(23):5629-5637. (Dec 1).
7. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 1999, 103:401-406.
8. Disanza A., Steffen A., Hertzog M., Frittoli E., Rottner K., Scita G. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell. Mol. Life Sci. 2005, 62:955-970.
9. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998, 90:1371-1388.
10. Floyd J.D., Nguyen D.T., Lobins R.L., Bashir Q., Doll D.C., Perry M.C. Cardiotoxicity of cancer therapy. J. Clin. Oncol. 2005, 23:7685-7696.
11. Gladwin M.T., Kim-Shapiro D.B. The functional nitrite reductase activity of the heme-globins. Blood 2008, 112(7):2636-2647. (Oct 1).
12. Gong F., Tang H., Lin Y., Gu W., Wang W., Kang M. Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr. Int. 2005, 47:242-247.
13. Gruetter C.A., Barry B.K., McNamara D.B., Gruetter D.Y., Kadowitz P.J., Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J. Cyclic Nucleotide Res. 1979, 5:211-224.
14. Guven A., Yavuz O., Cam M., Ercan F., Bukan N., Comunoglu C. Melatonin protects against epirubicin-induced cardiotoxicity. Acta Histochem. 2007, 109:52-60.
15. Haran E.F., Maretzek A.F., Goldberg I., Horowitz A., Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res. 1994, 54:5511-5514.
16. Hong R.A., Iimura T., Sumida K.N., Eager R.M. Cardio-oncology/onco-cardiology. Clin. Cardiol. 2010, 33:733-737.
17. Hozumi Y., Kawano M., Saito T., Miyata M. Effect of tamoxifen on serum lipid metabolism. J. Clin. Endocrinol. Metab. 1998, 83:1633-1635.
18. Ignarro L.J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1989, 65:1-21.
19. Ignarro L.J. Heme-dependent activation of guanylate cyclase by nitric oxide: a novel signal transduction mechanism. Blood Vessels 1991, 28:67-73.
20. Isenberg J.S., Ridnour L.A., Thomas D.D., Wink D.A., Roberts D.D., Espey M.G. Guanylyl cyclase-dependent chemotaxis of endothelial cells in response to nitric oxide gradients. Free Radic. Biol. Med. 2006, 40:1028-1033.
21. Isenberg J.S., Martin-Manso G., Maxhimer J.B., Roberts D.D. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat. Rev. Cancer 2009, 9:182-194.
22. Kanof, et al. Immunologic studies in humans. Current Protocols in Immunology 1993, John Wiley & Sons, New York, (Section 1, unit 7.1). J.E. Coligan (Ed.).
23. Kolluru G.K., Tamilarasan K.P., Rajkumar A.S., Geetha Priya S., Rajaram M., Saleem N.K., Majumder S., Jaffar Ali B.M., Illavazagan G., Chatterjee S. Nitric oxide/cGMP protects endothelial cells from hypoxia-mediated leakiness. Eur. J. Cell Biol. 2008, 87:147-161.
24. Kong D., Melo L.G., Mangi A.A., Zhang L., Lopez-Ilasaca M., Perrella M.A., Liew C.C., Pratt R.E., Dzau V.J. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004, 109:1769-1775.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 15:680-685.
26. Li H., Liu X., Cui H., Chen Y.R., Cardounel A.J., Zweier J.L. Characterization of the mechanism of cytochrome P450 reductase-cytochrome P450-mediated nitric oxide and nitrosothiol generation from organic nitrates. J. Biol. Chem. 2006, 281:12546-12554.
27. Liu J., Garcia-Cardena G., Sessa W.C. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 1996, 35:13277-13281.
28. Majumder S., Rajaram M., Muley A., Reddy H.S., Tamilarasan K.P., Kolluru G.K., Sinha S., Siamwala J.H., Gupta R., Ilavarasan R., Venkataraman S., Sivakumar K.C., Anishetty S., Kumar P.G., Chatterjee S. Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase. Br. J. Pharmacol. 2009, 158:1720-1734.
29. Maney S.K., Johnson A.M., Sampath Kumar A., Nair V., Santhosh Kumar T.R., Kartha C.C. Effect of apoptosis-inducing antitumor agents on endocardial endothelial cells. Cardiovasc. Toxicol. 2011, 11:253-262.
30. Mendelsohn M.E. Non genomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?. Circ. Res. 2000, 87:956-960.
31. Mikaelian I., Buness A., de Vera-Mudry M.C., Kanwal C., Coluccio D., Rasmussen E., Char H.W., Carvajal V., Hilton H., Funk J., Hoflack J.C., Fielden M., Herting F., Dunn M., Suter-Dick L. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol. Sci. 2010, 117:144-151.
32. Mosseri M., Fingert H.J., Varticovski L., Chokshi S., Isner J.M. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993, 53:3028-3033.
33. Mukhopadhyay S., Xu F., Sehgal P.B. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1373-H1389.
34. Nims R.W., Cook J.C., Krishna M.C., Christodoulou D., Poore C.M., Miles A.M., Grisham M.B., Wink D.A. Colorimetric assays for nitric oxide and nitrogen oxide species formed from nitric oxide stock solutions and donor compounds. Methods Enzymol. 1996, 268:93-105.
35. Okura Y., Kawasaki T., Kanbayashi C., Sato N. A case of epirubicin-associated cardiotoxicity progressing to life-threatening heart failure and splenic thromboembolism. Intern. Med. 2012, 51:1355-1360.
36. Papapetropoulos A., Rudic R.D., Sessa W.C. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 1999, 43:509-520.
37. Robinson E.S., Khankin E.V., Choueiri T.K., Dhawan M.S., Rogers M.J., Karumanchi S.A., Humphreys B.D. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010, 56:1131-1136.
38. Rodgers K.R. Heme-based sensors in biological systems. Curr. Opin. Chem. Biol. 1999, 3:158-167.
39. Ryan U.S. Isolation and culture of pulmonary endothelial cells. Environ. Health Perspect. 1984, 56:103-114.
40. Schimmel K.J., Richel D.J., van den Brink R.B., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. 2004, 30:181-191.
41. Schmitz K.H., Prosnitz R.G., Schwartz A.L., Carver J.R. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012, 118:2270-2276.
42. Sclafani F., Carnaghi C., Colombo P., Bozzarelli S., De Vincenzo F., Rimassa L., Giorgetti P.L., Santoro A. Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer. Chemotherapy 2010, 56:203-207.
43. Sentürk T., Kanat O., Evrensel T., Aydinlar A. Capecitabine-induced cardiotoxicity mimicking myocardial infarction. Neth. Heart J. 2009, 17:277-280.
44. Sessa W.C. The nitric oxide synthase family of proteins. J. Vasc. Res. 1994, 31:131-143.
45. Sessa W.C., Garcia-Cardena G., Liu J., Keh A., Pollock J.S., Bradley J., Thiru S., Braverman I.M., Desai K.M. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J. Biol. Chem. 1995, 270:17641-17644.
46. Sevelda P., Mayerhofer K., Obermair A., Stolzlechner J., Kurz C. Thrombosis with paclitaxel. Lancet 1994, 343:727.
47. Siamwala J.H., Dias P.M., Majumder S., Joshi M.K., Sinkar V.P., Banerjee G., Chatterjee S. l-Theanine promotes nitric oxide production in endothelial cells through eNOS phosphorylation. J. Nutr. Biochem. 2013, 24:595-605.
48. Slordal L., Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006, 29:567-586.
49. Strumberg D., Brugge S., Korn M.W., Koeppen S., Ranft J., Scheiber G., Reiners C., Mockel C., Seeber S., Scheulen M.E. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol. 2002, 13:229-236.
50. Tamilarasan K.P., Kolluru G.K., Rajaram M., Indhumathy M., Saranya R., Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol. 2006, 7:17.
51. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
52. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997, 36:11293-11297.
53. Yang X.P., Liu Y.H., Shesely E.G., Bulagannawar M., Liu F., Carretero O.A. Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 1999, 34:24-30.
54. Yang H., Park S.H., Choi H.J., Moon Y. The integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF-beta). Carcinogenesis 2010, 31:703-711.